title: Lipophilicity in Drug Development: Too Much or Not Enough?
abstract: A round table discussion was held during the AAPS Annual Meeting on October 27, 2015, with the somewhat provocative topic of whether we need more or less lipophilic compounds in drug development. The session was attended by more than 250 participants, and the feedback was very positive as this round table became a forum for the exchange of ideas from scientists within the academia and industry. Most importantly, the discussion highlighted the difference in approaches to compound selection and development strategies in various companies and organizations. As moderators of this session, we are writing this report to highlight the points and counterpoints made at the session and to bring the importance of the dialogue and debate to the forefront of discussions on how to select the best drug development candidates to enable efficient delivery and, hence, treatment of diseases.
authors.affiliation: Department of Pharmacy, Uppsala University, Uppsala Biomedical Centre, P.O. Box 580, SE-751 23, Uppsala, Sweden. christel.bergstrom@farmaci.uu.se.
authors.forename: Christel A S
authors.initials: CAS
authors.lastname: Bergström
authors.affiliation: Pharmaceutics Department, Teva Branded Pharmaceutical R&D Inc, West Chester, Pennsylvania, USA.
authors.forename: Mehran
authors.initials: M
authors.lastname: Yazdanian
mesh_terms: D000818:Animals; D001315:Australia; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D016503:Drug Delivery Systems / Q000379:methods* / Q000639:trends; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects / Q000502:physiology*; D008055:Lipids / Q000008:administration & dosage / Q000737:chemistry*
chemical_list: D008055:Lipids